生物科技
Search documents
第六届辽洽会将于9月25日在沈阳启幕
Liao Ning Ri Bao· 2025-09-13 02:58
Group 1 - The sixth China Liaoning International Investment and Trade Fair (Liaoning Fair) will be held from September 25 to 28 in Shenyang, with the theme "New Era of Northeast Revitalization, New Journey of Win-Win Cooperation" [1] - This year's fair features three main characteristics: highlighting Northeast Asia elements, offering a richer array of activities, and attracting higher attention [1] - The event will include over 100 activities, with participation from dignitaries and envoys from more than 50 countries, as well as representatives from "World 500" and "Private 500" companies [1] Group 2 - The opening ceremony on September 25 will be a key event, attended by nearly 700 representatives from "World 500" companies, state-owned enterprises, private enterprises, and business associations [2] - A total of 181 key projects are expected to be signed during the fair, showcasing the achievements of the province's revitalization efforts [2] - The fair will host four "Invest in Liaoning" international economic and trade matching activities, and several bilateral cooperation events with Japan, Mongolia, and Uzbekistan [2] Group 3 - A series of supporting activities will include sharing sessions on new productivity themes, featuring speakers from China Export & Credit Insurance Corporation and BGI Group [3] - A total of 46 economic and trade investment-related supporting activities and 63 cultural tourism brand activities will be organized by various cities during the fair [3] - The theme exhibition will showcase the results of the comprehensive revitalization efforts, including various specialized pavilions [3] Group 4 - The second Liaoning Business Conference and the 2025 Pujiang Innovation Forum Liaoning Sub-Forum will be significant components of this year's fair [4] - The Liaoning Business Conference will attract over 600 representatives from Liaoning businesses across 28 provinces and nearly 40 countries [4] - The 2025 Shenyang-Korea Investment and Trade Expo will coincide with the Liaoning Fair, featuring activities aimed at promoting local industries such as esports and cultural entertainment [4]
国常会研究完善海外综合服务体系,为出海企业提供有力支撑
Di Yi Cai Jing· 2025-09-13 02:21
Core Insights - The Chinese government is enhancing the overseas comprehensive service system to support enterprises in international cooperation and competition [1][5][6] - There is a growing demand for high-quality overseas comprehensive services as Chinese companies increasingly seek to expand internationally [3][4][5] Group 1: Government Initiatives - The State Council is focusing on improving the overseas comprehensive service system, integrating resources in legal, financial, and logistics services [1][6] - The government aims to establish overseas service stations in key countries and support local areas in creating comprehensive service ports for outbound enterprises [1][6][7] Group 2: Investment and Trade Statistics - China's foreign direct investment (FDI) stock has reached $3.1 trillion, maintaining a top-three global position for eight consecutive years [3] - In 2024, China's FDI flow is projected to be $192.2 billion, an 8.4% increase from the previous year, representing 11.9% of global investment flow [3] Group 3: Business Environment - The global economic recovery is challenging, with increasing competition and trade barriers, leading to a heightened need for quality overseas services [5] - Chinese enterprises are actively pursuing internationalization, particularly in sectors like semiconductors, automotive, renewable energy, and biotechnology [4]
QDII基金总规模年内增长26.5%
Zheng Quan Ri Bao· 2025-09-12 16:15
Group 1: QDII Fund Overview - As of September 12, the total number of QDII funds reached 314, with a total scale of 673 billion yuan, an increase of 141 billion yuan from the beginning of the year, representing a growth rate of 26.5% [1] - Among these, there are 215 equity QDII funds with a scale of 567.7 billion yuan, which accounts for the highest proportion in terms of both number and scale [1] - The significant growth in QDII fund scale this year reflects an increased demand for global asset allocation and improved risk tolerance among investors, influenced by the performance of certain QDII funds [1] Group 2: Performance of QDII Funds - The Hong Kong stock market has performed well this year, contributing to the strong performance of several QDII funds, with 25 funds showing a net value growth rate exceeding 80%, and some surpassing 100% [1] - Thematic funds focusing on innovative drugs and biotechnology have shown particularly strong performance [1] - Market experts attribute the strong performance of QDII funds to ample liquidity in the Hong Kong market and a robust valuation recovery, especially in sectors like innovative drugs, consumption, and technology [1] Group 3: Biopharmaceutical Industry Insights - The biopharmaceutical sector, including gene editing and synthetic biology, is recognized as a key driver for the development of new productive forces in China and is crucial for building a healthy China [2] - The long-term development of the biopharmaceutical industry is fundamentally driven by rigid demand, making it an attractive investment area for many investors [2] - Recent favorable policies in the domestic pharmaceutical industry support the development of innovative drugs across the entire chain, accelerating industry transformation [2]
南非比勒陀利亚大学研发出新型皮肤替代产品
Zhong Guo Xin Wen Wang· 2025-09-12 10:09
南非比勒陀利亚大学研发出新型皮肤替代产品 中新网约翰内斯堡9月12日电 南非广播公司12日报道称,南非比勒陀利亚大学新研发出一种新型皮肤替 代产品"无细胞真皮支架(ADS)",为未来3D生物打印天然皮肤铺平道路,成为传统皮肤移植的替代方 案。 该研究负责人哈菲扎·帕卡尔(Doctor Hafiza Parkar)介绍,无细胞真皮支架是一种用于严重创口的皮肤替 代产品,能够模拟人体皮肤,在动物实验中已显示出加速愈合的效果。 帕卡尔说,它的作用是为机体提供一个框架,以便长出新的健康组织。动物实验显示,它能减少移植中 常见的排斥反应,同时加快愈合速度,对于烧伤、溃疡等复杂创面尤其有效。(完) 来源:中国新闻网 编辑:陈俊明 广告等商务合作,请点击这里 本文为转载内容,授权事宜请联系原著作权人 中新经纬版权所有,未经书面授权,任何单位及个人不得转载、摘编或以其它方式使用。 关注中新经纬微信公众号(微信搜索"中新经纬"或"jwview"),看更多精彩财经资讯。 ...
2025年《麻省理工科技评论》“35岁以下科技创新35人”发布!
机器人圈· 2025-09-12 10:05
Core Viewpoint - The article highlights the achievements of 35 innovators under the age of 35 in various fields such as climate and energy, artificial intelligence, biotechnology, computing, and materials science, showcasing their groundbreaking contributions and potential impact on their respective industries [6][11][60]. Climate and Energy - Innovators in this sector are developing advanced technologies for decarbonization, with applications across shipping, fashion, and other industries. They are also exploring new methods for sustainable energy and innovative uses for carbon capture [11]. - Iwnetim Abate is working on producing ammonia using underground heat and pressure, aiming to reduce carbon emissions associated with traditional ammonia production, which contributes 1% to 2% of global CO2 emissions [13]. - Sarah Lamaison's company, Dioxycle, is developing a method to produce chemicals using electricity instead of fossil fuels, significantly reducing greenhouse gas emissions [16][17]. - Gaël Gobaille-Shaw's Mission Zero focuses on direct air capture technology to extract CO2 from the atmosphere, while his second company, Supercritical, aims to produce hydrogen efficiently [19][20]. Artificial Intelligence - Aditya Grover has developed ClimaX, an AI model that predicts weather and climate events, utilizing extensive datasets for improved accuracy [22][23]. - Neel Nanda is researching the interpretability of AI models to ensure their safe and beneficial development, focusing on understanding the decision-making processes of these models [34][35]. - Mark Chen has led advancements in AI models for image processing and code generation, contributing to the development of OpenAI's DALL·E and Codex [38][39]. - Akari Asai is working on retrieval-augmented generation technology to reduce AI hallucinations by allowing models to reference stored data before generating responses [51][52]. Biotechnology - Christian Kramme's company, Gameto, is developing artificial ovarian technology to assist IVF patients, aiming to reduce hormonal injections and stress during the process [62][63]. - Kevin Eisenfrats founded Contraline to create a long-lasting male contraceptive gel, with ongoing clinical trials to validate its effectiveness [64][65]. Computing and Materials Science - Pierre Forin's company, Calcarea, is developing a system to capture and store CO2 emissions from ships, with plans for commercial deployment by 2027 or 2028 [28][29]. - Neeka Mashouf's Rubi Laboratories is innovating a method to produce textiles by extracting CO2 directly from the atmosphere, aiming for sustainable fashion solutions [25][26].
“悦秘境”抑菌液打造医研企协同创新模式
Jing Ji Wang· 2025-09-12 09:41
Core Insights - Beijing Saiweisen International Biotechnology Co., Ltd. launched the brand "Yue Mijing," redefining women's intimate care standards through innovative solutions backed by patented technologies [1][2] - The company emphasizes supply chain management and quality control, sourcing key raw materials from biotech firms with proprietary technologies [1] - The growth of the "she economy" and the increasing health awareness among women, particularly those born in the 90s and 00s, are driving the expansion of the female consumer market [1] Product Innovation - The "Yue Mijing" antibacterial solution addresses industry pain points by utilizing "temperature-sensitive phase change technology," allowing the product to transition from liquid to gel at body temperature [2] - Clinical tests indicate that the product effectively inhibits bacteria such as Staphylococcus aureus and E. coli while being naturally expelled from the body, a feature lacking in existing products [2] - The product's formulation includes a proprietary blend of herbal extracts, enhancing its antioxidant, anti-inflammatory, and antibacterial properties [2] Market Context - The intimate care product market shows a significant demand, with intimate care liquids accounting for 48.8% of the market share, yet traditional products face challenges in absorption efficiency and safety [1] - Analysts highlight that many existing products suffer from a lack of research and development focus, contrasting with Saiweisen's commitment to innovation and collaboration with clinical experts [2]
港股异动|领航医药生物科技一度跌22% 股价创近2个月新低
Ge Long Hui· 2025-09-12 08:05
Core Viewpoint - The stock price of Pioneer Pharma Biotechnology (0399.HK) experienced a significant drop of 22.12% to HKD 0.405, marking a nearly two-month low since July 21 [1] Group 1: Company Announcement - Pioneer Pharma announced a placement agreement with China Northern Securities Group, set for August 21, 2025, to issue up to 145 million shares at a placement price of HKD 0.415 per share [1] - The board declared that the placement agreement became invalid as the conditions precedent were not met by September 11, 2025, resulting in the cancellation of the placement [1] Group 2: Financial Implications - The company had previously announced on August 21 that it aimed to raise HKD 58.825 million from the placement of 145 million shares, with the proceeds intended for funding the development of its blockchain technology business [1] - Following the announcement of the placement on August 22, the stock surged by 10.87% [1]
美国8月核心CPI同比增长3.1%,强化市场对美联储降息的押注
Sou Hu Cai Jing· 2025-09-12 05:52
Core Insights - The U.S. Labor Department reported that the Consumer Price Index (CPI) rose by 2.9% year-on-year in August, while the core CPI increased by 3.1%, aligning with market expectations, which strengthens the market's bets on a potential interest rate cut by the Federal Reserve [1] Group 1: Market Implications - A potential interest rate cut could lead to a weaker U.S. dollar, which may drive capital back to emerging markets, benefiting the Hong Kong stock market that has a high proportion of foreign investment [1] - The technology sector, being liquidity-sensitive, is likely to be the first to benefit from expectations of monetary easing [1] Group 2: Sector Analysis - A shift towards a looser interest rate environment would help reduce financing costs for technology companies in Hong Kong, particularly in high R&D sectors like biotechnology and the internet, alleviating pressure on valuation discount rates and improving long-term profit expectations [1] - Additionally, a rate cut may stimulate a rise in global risk appetite, enhancing market sentiment for the technology growth sector [1] - Technology companies, known for their resilience and growth attributes, tend to exhibit stronger upside potential in a loose monetary environment [1] Group 3: Investment Vehicles - Relevant ETFs for the Hong Kong technology sector include the Hong Kong Stock Connect Technology ETF (159101) and the Hang Seng Internet ETF (513330) [1]
港股午评:恒指涨1.53%,科指涨2.18%
Nan Fang Du Shi Bao· 2025-09-12 05:09
Market Performance - The Hang Seng Index rose by 1.53% at midday on the 12th [2] - The Hang Seng Tech Index increased by 2.18% [2] - The Hong Kong Stock Connect ETF (159318) gained 0.77% [2] - The Hong Kong Tech ETF (159751) saw an increase of 0.94% [2] Sector Performance - The metals and mining sector, along with the machinery manufacturing sector, showed strong gains [2] - The diversified REITs and biotechnology sectors experienced the largest declines [2] Individual Stock Movements - Baidu Group-SW surged by 8.54% [2] - China Hongqiao increased by 6.06% [2] - Alibaba-WR rose by 6.03% and Alibaba-W by 5.93% [2] - China Aluminum gained 5.92% [2] - Luoyang Molybdenum rose by 5.28% [2] - Kangfang Biotech increased by 4.38% [2] - Yimeng Biotech-B fell by 5.18% [2] - Hongteng Precision Technology dropped by 5.47% [2] - Yaojie Ankang-B surged over 55% [2] - Evergrande Property increased by 30.43% [2]
兰州大学发表最新Cell子刊论文
生物世界· 2025-09-12 04:07
Core Viewpoint - The study presents a novel method for real-time diagnosis of cholangiocarcinoma (CCA) by combining optical fiber biosensors based on bile clusterin with digestive endoscopy, addressing the urgent need for improved diagnostic techniques for this aggressive cancer type [2][10]. Summary by Sections Diagnosis Challenges - Cholangiocarcinoma is a highly malignant tumor with a poor prognosis, characterized by late diagnosis due to non-specific early symptoms, resulting in a 5-year survival rate of only 7%-20% [2]. Research Findings - The research team identified clusterin (CLU) as a promising biomarker for CCA through proteomic analysis of bile and cell supernatants, highlighting its overexpression in various cancers [5]. - The optical fiber biosensor technology, particularly surface plasmon resonance (SPR), was utilized for its high sensitivity and stability in detecting biological markers [5]. Methodology - The study involved 583 subjects and two rounds of proteomic analysis to screen and validate biomarkers for CCA, leading to the development of an SPR-based optical fiber biosensor [6]. - The biosensor demonstrated a high correlation coefficient of 0.989 and could accurately detect varying concentrations of CLU, with a detection time of 2 seconds and an area under the curve (AUC) of 0.854 [7]. Clinical Application - The CLU optical fiber biosensor was successfully integrated with digestive endoscopy, allowing for real-time in vivo diagnosis of CCA, with results aligning with postoperative pathology findings in patients [8][10].